natgillin/translations-raw huggingface dataset:
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Bolniki z dejavniki tveganja
Acute prerenal failure Renal impairment 
Ledvična bolezen Akutna predledvična odpoved Ledvična okvara
See leaflet for further information. 
Dodatne informacije so v navodilu za uporabo.
• The critical organ is the bone marrow, however, with the recommended Lutathera cumulative dose of 29,600 MBq (4 administrations of 7,400 MBq), no correlation between hematologic toxicity and the total radioactivity administered or bone marrow absorbed dose has been observed either in Erasmus phase I/II or in NETTER-1 phase III study. 
• kritičen organ je kostni mozeg, vendar pri priporočenem skupnem odmerku zdravila Lutathera v višini 29,600 MBq (4 aplikacije po 7.400 MBq) v študijah Erasmus I./II.
Scheme of instructions for dose modifications 
Preglednica 5: Navodila za prilagajanje odmerka
The adequate position of the catheter should be checked before and during infusion. 
Pred in med infundiranjem je treba preverjati, ali je položaj katetra pravilen.
Cases of irreversible hematological pathologies, i.e., premalignant and malignant blood neoplasms (i.e., myelodysplastic syndrome and acute myeloid leukemia, respectively) have been reported following Lutathera treatment. 
Po zdravljenju z zdravilom Lutathera so poročali o primerih nepovratnih hematoloških patologij, tj. predmalignih in malignih krvnih neoplazmah (tj. mielodisplastičnega sindroma oziroma akutne mieloidne levkemije).
Hepatic encephalopathy Paraesthesia Parosmia 
Mravljinčenje Hepatična encefalopatija
What Lutathera contains - The active substance is lutetium (177Lu) oxodotreotide. 
Kaj vsebuje zdravilo Lutathera - Učinkovina je lutecijev (177Lu) oksodotreotid.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
It is not recommended to decrease the amount of amino acid solution in case of Lutathera dose adaptation. 
V primeru prilagoditve odmerka zdravila Lutathera ni priporočljivo zmanjšati količino raztopine aminokislin.
If you get any side effects, talk to your doctor. 
Če opazite katerega koli izmed neželenih učinkov, se posvetujte, se posvetujte z zdravnikom.
In spite of an observed significant selective B-cell depletion, no increase in the rate of infectious complications occurs after PRRT. 
Kljub opaženi pomembni selektivni izgubi B-celic se zvečanje pojavnosti komplikacij z okužbami po radionuklidni terapiji s peptidnimi receptorji (PRRT, peptide receptor radionuclide therapy) ne pojavi.
Suitable precautions in accordance with national regulations should be taken concerning the activity eliminated by the patients in order to avoid any contaminations. 
Za preprečevanje kakršne koli kontaminacije vezane na aktivnost, ki jo izločijo bolniki,
Refractory cytopenia with multilineage dysplasia (Myelodysplastic syndrome) 
Refraktorna citopenija z displazijo več celičnih linij (mielodisplastični sindrom)
Pancreatitis acute Rectal haemorrhage Melaena 
Akutni pankreatitis Rektalna krvavitev Melena
Dishes and bathroom accessories Take special precautions during the 7 days after treatment: - Flush all wipes and/or toilet paper down the toilet immediately after use, - Always wash your hands well after using the toilet, - Take a shower every day, - Flush any tissues or any other items that contain anything from your body, such as blood, urine and faeces down the toilet. 
- vse robčke in/ali ves toaletni papir takoj po uporabi odplaknite v stranišču; - po uporabi stranišča si vedno umijte roke;
To avoid treatment-related nausea and vomiting, an intravenous bolus of an antiemetic medicinal product should be injected 30 minutes before the start of amino acid solution infusion (see section 
Z zdravljenjem povezanima navzei in bruhanju se izognemo z intravenskim bolusom antiemetika, ki ga je treba injicirati 30 minut pred začetkom infundiranja raztopine aminokislin (glejte poglavje 4.2).
Disposable waterproof gloves should be worn. 
Nositi je treba vodotesne rokavice za enkratno uporabo.
Figure 4. 
in 4.4.
Radiation dose to specific organs, which may not be the target organ of therapy, can be influenced significantly by pathophysiological changes induced by the disease process. 
Patofiziološke spremembe, ki jih sproži bolezenski proces lahko bistveno vplivajo na odmerek sevanja za posamezne organe, ki niso ciljni organi pri zdravljenju.
Considering the high quantity of amino acids and the significant volume that commercially available solutions may require to meet the above specifications, the compounded solution is considered the medicinal product of choice, due to its lower total volume to be infused and lower osmolarity. 
Sestavljena raztopina zaradi nižjega skupnega volumna, ki ga je treba infundirati, in nižje osmolarnosti predstavlja zdravilo prve izbire glede na veliko količino aminokislin in znaten volumen, ki bo morda potreben, da bi komercialno dostopne raztopine lahko ustrezale zgoraj navedenim specifikacijam.
Red Marrow 
Rdeči kostni mozeg
2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells. 
Lutecij-177 (177Lu) je radionuklid, ki oddaja β-, z največjim razponom penetracije v tkivo 2,2 mm (srednji razpon penetracije je 0,67 mm), kar zadostuje za uničenje ciljanih tumorskih celic z omejenim učinkom na sosednje normalne celice.
Rates lower than 320 mL/h are not recommended for commercial solutions. 
Pri uporabi komercialnih raztopin so odsvetovane hitrosti, nižje od 320 ml/h.
− A pair of tongs (for Lutathera vial handling) 
− klešče (za prijemanje viale zdravila Lutathera);
Excipient with known effect Each mL of solution contains 0.14 mmol (3.2 mg) of sodium. 
En ml raztopine vsebuje 0,14 mmol (3,2 mg) natrija.
Tabulated list of adverse reactions The adverse reactions are listed in Table 7 according to the frequency and the MedDRA System Organ 
Neželeni učinki so navedeni v preglednici 7 glede na pogostnost in organske sisteme MedDRA (SOC).
After administration of Lutathera 
Po apliciranju zdravila Lutathera
Two hundred thirty-one (231) patients have been randomized to receive either Lutathera (n=117) or octreotide LAR (n=114). 
(n = 117) ali oktreotida LAR (n = 114).
Includes Headache and migraine 
Bolečina v ustih in žrelu
Acetic acid Sodium acetate Gentisic acid Ascorbic acid Pentetic acid Sodium chloride Sodium hydroxide Water for injections 
6.1 Seznam pomožnih snovi ocetna kislina natrijev acetat gentizinska kislina askorbinska kislina pentetinska kislina natrijev klorid natrijev hidroksid voda za injekcije
Lutathera should always be infused through an intravenous catheter placed exclusively for its infusion. 
Pravila za zaščito proti sevanju Zdravilo Lutathera je treba vedno infundirati po intravenskem katetru, ki je nameščen izključno za to infuzijo.
PFS and OS observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NET - (FAS, N=360) 
faze pri nizozemskih bolnikih z GEP in bronhialnimi NET - (FAS, N=360)
Volumetric activity at calibration time: 370 MBq/mL - {DD/MM/YYYY hh:mm UTC} Activity at infusion time: {Z} MBq - {DD/MM/YYYY hh:mm UTC} 
Volumetrična aktivnost v času umerjanja: 370 MBq/ml - {DD/MM/LLLL uu:mm UTC} Aktivnost v času infundiranja: {Z} MBq - {DD/MM/LLLL uu:mm UTC}
Lutathera with sodium chloride 9 mg/mL (0.9%) solution for injection 
Zdravilo Lutathera z natrijevim kloridom 9 mg/ml (0,9 %) raztopino za injiciranje 60
Pregnancy No studies on animal reproductive function have been conducted with lutetium (177Lu) oxodotreotide. 
Izvedena ni bila nobena študija o sposobnosti za razmnoževanje na živalih z lutecijevim (177Lu) oksodotreotidom.
Low white blood cell count (leukopenia or neutropenia), muscle pain, temporal partial hair loss (alopecia), abdominal distension (feeling bloated), diarrhoea, dizziness, injection site reaction or swelling, disturbed taste, pain in the site of injection, headache, high or low blood pressure, peripheral oedema, abnormal results of renal blood test (increased creatinine), abdominal pain (general and upper), constipation, abnormal results of liver blood test, flushing and hot flushes, increased sugar level in the blood, fainting, renal failure (including acute injury), dehydration, heartburn (dyspepsia), blood in urine, abnormal results of urine test (presence of serum proteins), decrease in function of thyroid, shortness of breath, inflammation of stomach (gastritis), abnormally high amounts of bile pigment (bilirubin) in the blood (Hyperbilirubinemia), abnormal results of blood test (Hypomagnesaemia and hyponatraemia), influenza like illness, chills, bone marrow cancer (myelodysplastic syndrome), blood transfusion. 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): zmanjšano število belih krvnih celic (levkopenija ali nevtropenija), bolečina v mišicah, začasna delna izguba las in dlak (alopecija), napihnjenost trebuha (občutek napihnjenosti), driska, omotica, reakcija ali oteklina na mestu injiciranja, motnje okušanja, bolečina na mestu injiciranja, glavobol, visok ali nizek krvni tlak, periferni edem, nenormalni rezultati krvnih preiskav delovanja ledvic (zvišan kreatinin), bolečina v trebuhu (splošno in v zgornjem delu), zaprtje, nenormalni rezultati preiskav jetrne krvi, zardevanje in vročinski oblivi, zvišana raven sladkorja v krvi, omedlevica, ledvična odpoved (vključno z akutno poškodbo), dehidracija, zgaga (prebavne motnje), kri v urinu, nenormalni rezultati preiskav urina (prisotnost proteinov v serumu), zmanjšanje delovanja ščitnice, zasoplost, vnetje želodca (gastritis), nenormalno velika količina žolčnega barvila (bilirubina) v krvi
Hepatic impairment 
Hepatični zastoj
Given the mechanism of action and the tolerance profile of Lutathera (see section 4.8), it is not recommended to start treatment in the following cases: 
Glede na mehanizem delovanja in profil tolerance za zdravilo Lutathera (glejte poglavje 4.8)
Composition of the standard amino acid solution 
Preglednica 1: Sestava standardne raztopine aminokislin Sestavina
NAME OF THE MEDICINAL PRODUCT Lutathera 370 MBq/mL solution for infusion 
IME ZDRAVILA Lutathera 370 MBq/ml raztopina za infundiranje
If your partner is pregnant, extend this time to 15 days. 
- spite v ločenih posteljah na razdalji najmanj 1 metra; če je vaša partnerica noseča, ta čas podaljšajte na 15 dni.
Clear, colourless to slightly yellow solution. 
FARMACEVTSKA OBLIKA raztopina za infundiranje Bistra, brezbarvna do nekoliko rumena raztopina.
Genetic consultation is recommended if you wish to have children after treatment. 
Če želite imeti po zdravljenju otroke, je priporočljivo genetsko svetovanje.
The pharmacokinetic profile of lutetium (177Lu) oxodotreotide in patients with severe hepatic impairment has not been studied, 
Farmakokinetični profil lutecijevega (177Lu) oksodotreotida pri bolnikih s hudo jetrno okvaro ni bil raziskan, zato zdravljenje z zdravilom
Arginine content 
Vsebnost arginina
Secondary hypothyroidism Hypothyroidism Diabetes mellitus 
Hipotiroidizem Diabetes mellitus Karcinoidna kriza Hipotiroidizem
Genetic consultation is recommended if the patient wishes to have children after treatment. 
Če želi bolnik po zdravljenju imeti otroke, je priporočljivo genetsko svetovanje.
For information on the use in patients with renal impairment, see section 4.2. 
Za informacijo o uporabi pri bolnikih z ledvično okvaro glejte poglavje 4.2.
oxodotreotide through the proximal tubules, resulting in a significant reduction in the kidney radiation dose (see section 4.2). 
Raztopina aminokislin bo pomagala zmanjšati reabsorpcijo lutecijevega (177Lu) oksodotreotida skozi proksimalne tubule, kar bo omogočilo pomembno zmanjšanje odmerka sevanja v ledvicah (glejte poglavje 4.2).
Based on the data collected during the Erasmus phase I/II and NETTER-1 phase III studies, lutetium (177Lu) oxodotreotide is primarily eliminated by renal excretion: about 60% of the medicinal product is eliminated in the urine within 24 hours, and about 65% within 48 hours following the administration. 
oksodotreotid primarno izloča preko ledvic: približno 60 % zdravila se izloči v urin v 24 urah in približno 65 % v 48 urah po aplikaciji.
The infusion of the amino acid solution should start 30 minutes prior to start of Lutathera infusion. 
Infundiranje raztopine aminokislin je treba začeti 30 minut pred začetkom infundiranja zdravila Lutathera.
Premedication with antiemetics should be injected 30 minutes before the start of amino acid solution infusion. 
Premedikacijo z antiemetiki je treba injicirati 30 minut pred začetkom infuzije raztopine aminokislin.
Nevertheless, the general condition of the patient and the possible adverse reactions to treatment must be taken into account before driving or using machines. 
Pred vožnjo ali upravljanjem strojev pa je treba vseeno upoštevati splošno stanje bolnika in možne neželene učinke zdravljenja.
Nephrotoxicity Lutetium (177Lu) oxodotreotide is excreted by the kidney. 
Nefrotoksičnost Lutecijev (177Lu) oksodotreotid se izloča skozi ledvice.
Hyperglycaemia Dehydration Hypomagnesaemia Hyponatremia 
Hiperglikemija Dehidracija Hipomagnezemija Hiponatriemija
− One vial of Lutathera 
− ena viala zdravila Lutathera;
PFS = Progression free survival; OS = Overall survival * Includes Foregut, Midgut and Hindgut; **Foregut NETs other than bronchial and pancreatic 
PFS (Progression Free Survival) = preživetje brez napredovanja bolezni; OS (Overal Survival) = stopnja preživetja
Conjunctivitis Respiratory tract infection Cystitis 
Konjunktivitis Okužbe dihal Cistitis
Secondary malignant neoplasms 
Sekundarni maligni tumorji
• Kidney failure with creatinine clearance < 30 mL/min 
• odpoved ledvic z očistkom kreatinina < 30 ml/min.
Lutathera contains sodium 
Zdravilo Lutathera vsebuje natrij.
PFS Kaplan Meier curves of patients with progressive midgut carcinoid tumourcut-off date 30 June 2016 (NETTER-1 phase III study; FAS, N=231) 
Slika 4: PFS Kaplan Meier krivulje bolnikov s progresivnim karcinoidnim tumorjem v srednjem črevesju - končni datum za analizo 30. junij 2016 (študija NETTER 1 III. faze; FAS, N = 231)
This evidence confirms what has been previously observed in the Erasmus phase I/II study, in which HPLC analysis of a urine specimen collected 1 hour post administration of lutetium (177Lu) oxodotreotide from one patient receiving 1.85 MBq of lutetium (177Lu) oxodotreotide indicated that the main portion (91%) was excreted unchanged. 
faze, v kateri je analiza HPLC vzorca urina, zbranega 1 uro po aplikaciji lutecijevega (177Lu) oksodotreotida od enega bolnika, ki je prejel 1,85
For additional details about the treatment of patient with renal impairment see Table 5 in section 4.2 and section 4.4. 
Za dodatne informacije o zdravljenju bolnikov z blago do zmerno jetrno okvaro glejte preglednico 5 v poglavjih 4.2 in 4.4.
One mL of solution contains 370 MBq of lutetium (177Lu) oxodotreotide at the date and time of calibration. 
En ml raztopine vsebuje 370 MBq lutecijevega (177Lu) oksodotreotida ob datumu in uri umerjanja.
Lethargy Syncope 
Raztopina aminokislin
Lutathera 370 MBq/mL solution for infusion Lutetium (177Lu) oxodotreotide 
Lutathera 370 MBq/ml raztopina za infundiranje lutecijev (177Lu) oksodotreotid
Elderly: 
Starejši bolniki:
Discontinue Lutathera administrations in patients who have experienced or are at risk of any of the following conditions during treatment: 
Preglednica 3: Merila za dokončno ukinitev zdravljenja z zdravilom Lutathera Ukinitev aplikacije zdravila Lutathera pri bolnikih, ki so imeli ali pa zanje v času zdravljenja obstaja tveganje za pojav naslednjega:
Abdominal cavity drainage Dialysis 
Drenaža trebušne votline Dializa
How Lutathera is used 
Kako uporabljati zdravilo Lutathera
Antiemetic premedication should be administered 30 minutes before start of amino acid solution infusion. 
Premedikacijo z antiemetiki je treba aplicirati 30 minut pred začetkom infuzije raztopine aminokislin.
Hyperparathyroidism 
Hipertenzija7
There is no relevant use of Lutathera in the paediatric population in the indication of treatment of GEP-NETs (excluding neuroblastoma, neuroganglioblastoma, phaeochromocytoma). 
Pediatrična populacija Ni smotrne uporabe zdravila Lutathera pri pediatrični populaciji za indikacijo zdravljenja GEP-NET
PFS observed in the NETTER-1 phase III study in patients with progressive midgut carcinoid tumour - cut-off date 24 July 2015 (full analyses set (FAS), N=229) 
Preglednica 8: vrednost PFS, opažena v študiji NETTER-1 III. faze pri bolnikih s progresivnim karcinoidnim tumorjem v srednjem črevesju - končni datum za analizo 24. julij 2015 (celotna skupina bolnikov (FAS), N=229)
The European Medicines Agency has waived the obligation to submit the results of studies with Lutathera in all subsets of the paediatric population in the treatment of GEP-NETs (excluding neuroblastoma, neuroganglioblastoma, phaeochromocytoma). 
Lutathera za vse skupine pediatrične populacije pri zdravljenju GEP-NET (razen nevroblastoma,
PFS observed in the NETTER-1 phase III study in patients with progressive midgut carcinoid tumour - cut-off date 30 June 2016 (full analyses set (FAS), N=231) 
Preglednica 9: vrednost PFS, opažena v študiji NETTER 1 III. faze pri bolnikih s progresivnim karcinoidnim tumorjem v srednjem črevesju - končni datum za analizo 30. junij 2016 (celotna skupina bolnikov (FAS), N = 231)
EXPIRY DATE EXP: {DD MM YYYY hh:mm UTC} 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: {DD MM LLLL uu:mm UTC}
Breasts 
Pireksija
For information on the use in patients with hepatic impairment, see section 4.2. 
Za informacijo o uporabi pri bolnikih z jetrno insuficienco glejte poglavje 4.2.
Thrombocytopenia2 Lymphopenia3 
Trombocitopenija2Limfopenija3 Anemija4
If you get any side effects talk to your nuclear medicine doctor. 
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom nuklearne medicine.
PFS Kaplan Meier curves of patients with progressive midgut carcinoid tumour - cutoff date 24 July 2015 (NETTER-1 phase III study; FAS, N=229) 
Slika 3: PFS Kaplan Meier krivulje bolnikov s progresivnim karcinoidnim tumorjem v srednjem črevesju, - končni datum za analizo 24. julij 2015 (Študija NETTER-1 III. faze; FAS,
STATEMENT OF ACTIVE SUBSTANCE(S) One mL contains 370 MBq of lutetium (177Lu) oxodotreotide at calibration time. 
NAVEDBA ENE ALI VEČ UČINKOVIN En ml vsebuje 370 MBq lutecijevega (177Lu) oksodotreotida v času umerjanja.
The co-administration of amino acid solution decreases the kidney uptake, enhancing the elimination of radioactivity (see section 4.4). 
Sočasna aplikacija raztopine aminokislin zmanjša privzem v ledvicah, kar izboljša izločanje radioaktivnosti
Uncommon increased 
Zvečanje vrednosti
• Haematology (Haemoglobin [Hb], white blood count, platelet count) 
• hematologija (hemoglobin [Hb], število levkocitov in trombocitov).
PHARMACEUTICAL FORM Solution for infusion. 
FARMACEVTSKA OBLIKA IN VSEBINA Raztopina za infundiranje Viala št .
Dry mouth 
Trebušna slinavka
Upper Large Intestine Wall Heart Wall 
Stena srca Ledvice Jetra
Wait 12 weeks after the date of surgery to administer Lutathera. 
tednov po datumu kirurškega posega.
Acute myeloid leukaemia Acute leukaemia Chronic myelomonocytic leukaemia 
Akutna mieloidna levkemija Akutna levkemija
Toxicological studies with rats have demonstrated that a single intravenous injection of up to 4,550 MBq/kg was well tolerated and no deaths were observed. 
Toksikološke študije pri podganah so pokazale dobro prenašanje ene intravenske injekcije do
Unless your doctor has considered that the clinical benefit of the treatment overcomes the possible risks, you will not be given this medicine: - if you have received a previous external radiation therapy on more than 25% of your bone marrow - if you heart is seriously impaired - if you have seriously affected blood cell counts - if your liver is seriously impaired - if it appears that your tumour does not have sufficient somatostatin receptors 
- če imate resno okvaro srca; - če imate resno prizadeto število krvnih celic; - če imate resno okvaro jeter; - če se izkaže, da tumor nima zadostnih somatostatinskih receptorjev.
Malaise 
Konstipacija
NAME OF THE MEDICINAL PRODUCT Lutathera 370 MBq/mL solution for infusion Lutetium (177Lu) oxodotreotide 
IME ZDRAVILA IN POT(I) UPORABE Lutathera 370 MBq/ml raztopina za infundiranje lutecijev (177Lu) oksodotreotid intravenska uporaba
Occurrence of an intercurrent disease (e.g. urinary tract infection), which according to the physician could increase the risks associated to Lutathera administration. 
ki bi po mnenju zdravnika lahko povečale tveganja, povezana z aplikacijo zdravila Lutathera.
Dizziness Dysgeusia Headache10 
Omotica Disgevzija Glavobol10 Letargija Sinkopa
Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients. 
Ledvična okvara Pri teh bolnikih obstaja možnost povečane izpostavljenosti sevanju, zato je treba tehtno premisliti o aktivnosti, ki se jo aplicira.
Vial No.: {X} 
: {X}
The following table summarises the required procedures during a treatment course with Lutathera using the gravity method: 
Naslednja preglednica povzema zahtevane postopke med potekom zdravljenja z zdravilom Lutathera z gravitacijsko metodo: Preglednica 6: Postopek aplikacije antiemetika, raztopine aminokislin in zdravila Lutathera Aplicirana sredstva
Clavicle fracture 
Zlom ključnice
Start time (min) 
Čas začetka
Depending on the case, aspiration of extravasation fluid, sodium chloride 9 mg/mL (0.9%) solution for injection flush injection, or applying warm compresses or a heating pad to the infusion site to accelerate vasodilation should be considered. 
Odvisno od posameznega primera je treba razmisliti o uporabi aspiracije ekstravazacijske tekočine, izpiranje z injekcijo natrijevega klorida 9 mg/ml (0,9 %)
Careful consideration of the activity to be administered to patients with hepatic impairment is required since an increased radiation exposure is possible in these patients. 
Pri teh bolnikih obstaja možnost povečane izpostavljenosti sevanju, zato je treba pri bolnikih z jetrno okvaro tehtno premisliti o aktivnosti, ki se jo aplicira.
Gastrointestinal tube insertion Stent placement Abscess drainage Bone marrow harvest Polypectomy 
Vstavitev žilne opornice Drenaža abscesa Odvzem kostnega mozga Polipektomija
Blood lactate dehydrogenase 
Zvečanje vrednosti laktat dehidrogenaze v krvi Kateholamini v krvi
Fatigue1 
Utrujenost1
Refractory cytopenia with unilineage dysplasia Nephrogenic anaemia Bone marrow failure Thrombocytopenic purpura 
Refraktorna citopenija z displazijo ene celične linije Nefrogena anemija Odpoved kostnega mozga
Best response, ORR and DoR observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NETs - (FAS, N=360) 
Preglednica 10: Opažen najboljši odziv, ORR in DoR v študiji Erasmus I./II.
• The tubing line should be pre-filled with sodium chloride 9 mg/mL (0.9%) solution for injection and then connected with a venous catheter previously inserted to the patient's arm. 
Postopek priključitve cevke na vialo zdravila Lutathera (glejte sliko 2): • Vod cevke je treba predhodno napolniti z natrijevim kloridom 9 mg/ml (0,9 %) raztopino za injiciranje in nato priključiti na venski kateter, predhodno vstavljen v bolnikovo roko.
Use of toilets 
Jedilni pribor in kopalniški pripomočki
− Amino acid solution bag(s) 
− vrečka(-e) z raztopino aminokislin;
Major surgery. 
Večji kirurški poseg.
Blood creatinine increased GGT* increased ALAT** increased ASAT*** increased Blood ALP**** increased 
Zvečanje vrednosti GGT* Zvečanje vrednosti
Physical disability 
Telesna prizadetost
11 Includes injection site reaction, injection site hypersensibility, injection site induration, injection site swelling * Gamma-glutamyltransferase increased **Alanine amino transferase *** Aspartate amino transferase **** Alkaline phosphatase 
** Alanin-aminotransferaza *** Aspartat-aminotransferaza **** Alkalin fosfataza
• Patient guide 
Vodnik za bolnike